ESU

Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results

Clinical guidelines from the disciplines of cardiology and laboratory and emergency medicine have all emphasized the importance of cardiac markers in diagnosing or ruling out acute myocardial infarction. The measurement of cardiac troponins is especially useful in the large fraction of patients presenting with acute coronary syndrome (ACS) who have...

Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control

According to the American Diabetes Association, the total annual economic cost of diabetes in 2002 was estimated to be $132 billion, or one out of every 10 health care dollars spent in the United States. A chronic disease with no cure, diabetes is a group of diseases (including Type 1, Type 2, and gestational) marked by...

Cell Therapeutics, Inc. Management to Discuss Today's Announcement of Interim Pixantrone Study Results

SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- On Wednesday,July 11, 2007, at 1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m.Central European Time members of Cell Therapeutics, Inc.'s (CTI)management team will host a conference call to discuss today'sannouncement of the interim results of its phase II/III RAPID trialcomparing CHOP-R to CPOP-R, in which pixantrone is substituted fordoxor...

Sygnis Pharma AG announces date for presentation of clinical results

HEIDELBERG, Germany, 11 July 2007 – On 23 July SYGNIS PharmaAG will present the results of the clinical phase IIa study forAX200 (AXIS-study). AX200, a compound for the treatment of stroke, is the mostadvanced drug candidate in SYGNIS’ product pipeline. Theprimary aim of the study is to show safety and tolerability ofAX200 in acute stroke patients. The results of the AXIS-stud...

Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis

RIDGEFIELD, Conn., July 11, 2007 /PRNewswire/ -- Phase 3 resultsfrom the RE-NOVATE(TM) trial demonstrated that oral dabigatranetexilate once daily, administered for an average of 33 days, wasnon-inferior to enoxaparin, also administered for an average of 33days, in preventing venous thromboembolism (VTE) and all-causemortality after total hip replacement surgery. In this trial, therate o...

Positive Aggrastat Results Featured in the Journal of the American College of Cardiology

WINNIPEG, Manitoba - (July 11, 2007) Medicure Inc. (TSX:MPH;Amex:MCU), a cardiovascular focused, biopharmaceutical company,today announced that the two-year, follow-up results from theSTRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-ElutingStent Versus Abciximab and Bare Metal Stent In Acute MyocardialInfarct...

Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy

Positive interim results prompt request for meeting with FDA SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced today that interim results ofits phase II/III trial comparing CPOP-R, in which pixantrone issubstituted for doxorubicin in standard CHOP-R first-line treatmentof patients with aggressive non-Hodgkin's lymphoma (NHL), resultedin essentially al...

Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society

- Co-Injection of rHuPH20 with Humira Estimated to Increase theMaximal Steady State Subcutaneous Bioavailability from 64% to 100%- SAN DIEGO, July 09, 2007 /PRNewswire-FirstCall/ -- HalozymeTherapeutics, Inc. , a biopharmaceutical company developing andcommercializing recombinant human enzymes, today announced thatfinal results of the Enhanze(TM) Technology clinical trialdemonstrating im...

Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

- Results Fail to Demonstrate Meaningful Placebo Adjusted WeightLoss; Obesity Program to be Discontinued NEW YORK, July 09, 2007 /PRNewswire-FirstCall/ -- ManhattanPharmaceuticals, Inc. today announced results of the company's twoPhase 2a clinical trials of oral Oleoyl-estrone (OE). The resultsof both randomized, double-blind, placebo-controlled studies, onein common obesity and the other...

Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis

- Multinational Phase III Study Meets Primary Endpoint inRheumatoid Arthritis Patients Who Failed to Respond to Anti-tumorNecrosis Factor Treatments - NUTLEY, N.J., July 10, 2007 /PRNewswire/ -- Roche todayannounced that results from the Actemra Radiate (RheumAtoiDArthritIs Study in Anti-TNF FailurEs) trial successfully met itsprimary endpoint in patients with moderate to severe rheumatoi...

AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis

AM Pharma Continues Its Success with Positive Phase IIa ClinicalTrial Results First clinical Results Confirm Potential New Application of KeyProduct in AM-Pharma's Pipeline BUNNIK, The Netherlands, July 9, 2007-AM-Pharma B.V., thebiopharmaceutical company developing novel therapeutics to treatinfectious and inflammatory diseases, today announced the positiveclinical results of its...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor,Shows a Significant Reduction in Deep Vein Thrombosis and PulmonaryEmbolism Compared with Enoxaparin with Similarly Low BleedingRates GENEVA, July 8, 2007 - Late-breaking Phase III clinical trialdata presented today at the XXI International Society on Thrombosisand Haemostasis (ISTH) Congress demonstrate that once-daily...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase IIIclinical trial data presented today at the XXI InternationalSociety on Thrombosis and Haemostasis (ISTH) Congress demonstratethat once-daily rivaroxaban achieved superior efficacy in theprevention of venous thromboembolism (VTE) in patients undergoingknee replacement surgery in a head-to-head comparison withenoxaparin, the curren...

TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment

LOD, Israel--(BUSINESS WIRE)--Jul 9, 2007 - TransPharma MedicalLtd., a specialty pharmaceutical company focused on the developmentand commercialization of drug products utilizing a proprietaryactive transdermal drug delivery technology, announced todaypromising results of its phase I clinical trials demonstrating thesafety and pharmacokinetic profile of its ViaDerm-hPTH (1-34)product for th...

Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis

IRVINE, Calif.--(BUSINESS WIRE)--Jul 6, 2007 - Cobalis Corp.(OTCBB:CLSC), a pharmaceutical development company specializing inanti-allergy medications, today reported preliminary top-lineresults from two Phase III clinical trials for its drugPreHistin(TM) in patients with moderate to moderately severeseasonal allergic rhinitis, commonly known as hay fever. The trialsshowed very low symptom...

Genzyme Announces Results of Clinical Trial of Hylastan

CAMBRIDGE, Mass., July 05, 2007 /PRNewswire-FirstCall/ --Genzyme Corp. today announced top-line results from a pivotal studyinvestigating the safety and efficacy of hylastan in treating painin patients with osteoarthritis (OA) of the knee. Hylastan is beingdeveloped within Genzyme's program to introduce aviscosupplementation product that can be delivered through a singleknee injection. T...

Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis

SCHLIEREN (Zurich), Switzerland, July 3, 2007 - Cytos BiotechnologyAG (SWX:CYTN) announced today results from a phase IIa study withCYT003-QbG10 in atopic dermatitis. CYT003-QbG10 is animmunotherapeutic product candidate currently in development forthe treatment of allergic diseases. The present study aimed toassess safety, tolerability and exploratory efficacy of the productcandidate in a...

Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)

GHENT, Belgium, 2 July, 2007 -- Ablynx today announced positiveinterim results from the ongoing Phase I study of its leaddevelopment programme, ALX-0081, an anti-thrombotic treatment.ALX-0081 is a novel ´first-in-class´ therapeuticNanobody® targeting von Willebrand Factor (vWF), which canreduce the risk of thrombosis in patients with acute coronarysyndrome. The Pha...

Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)

SOUTH SAN FRANCISCO, July 02, 2007 /PRNewswire/ -- PortolaPharmaceuticals, Inc. announced today that it will present clinicaland preclinical data on its oral Factor Xa inhibitor and on itsintravenous and oral ADP receptor antagonist at the XXI Congress ofthe International Society of Thrombosis and Haemostasis (ISTH) inGeneva, Switzerland on July 6 through July 12, 2007. The EXPERT...

DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC

MIAMI--(MARKET WIRE) -- July 02, 2007 -- DOR BioPharma, Inc.(OTCBB: DORB) ("DOR" or the "Company") announced today that thefirst results from testing of a multivalent form of its botulinumtoxin vaccine, BT-VACC™, have been published in the journalInfection and Immunity (Ravichandran et al., 2007, Infection andImmunity, v. 75, p. 3043 ). These results are the first thatdescribe the...

Alkermes Announces Positive Results from Phase 1/2 Clinical Study of ALKS 29

Company to Proceed with Development Program for Oral Compoundsto Treat Alcohol Dependence CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 2, 2007--Alkermes, Inc.(Nasdaq: ALKS) today announced positive preliminary results from aclinical trial of ALKS 29 in alcohol dependent patients. Based onthese results, the company plans to move forward with itsdevelopment program for oral product...

Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - CyclacelPharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced todaythe results from two Phase II non-randomized studies of seliciclibfixed dose combinations. In one study seliciclib was given incombination with gemcitabine and cisplatin and in another withdocetaxel in patients with advanced non-small cell lung cancer(NSCLC).<p...

Biotec Pharmacon Announces Preliminary Results from the Sloan-Kettering Clinical Study

TROMSØ, Norway, June 29, 2007-Preliminary results fromthe immunotherapeutic cancer study at Memorial Sloan-KetteringCancer Center show a very good safety profile for SBG. Furthermore,encouraging responses on cancer development have been observedamong several patients that have been treated with SBG incombination with the monoclonal antibody against neuroblastoma. In line wit...

Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness

TARRYTOWN, N.Y. & MADISON, N.J.--(BUSINESS WIRE)--Jun 28, 2007- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and WyethPharmaceuticals, a division of Wyeth (NYSE: WYE), today announcedpositive results from a three-month open-label extension study ofsubcutaneous methylnaltrexone for the treatment of opioid-inducedconstipation (OIC) in patients with advanced illness. The resultsare sched...

Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company

Statement by Sandra C. Raymond, President & CEO of the LupusFoundation of America, Inc. WASHINGTON, June 27, 2007 /PRNewswire-USNewswire/ -- The LupusFoundation of America, Inc. and more than 1.5 million Americanswith lupus have been awaiting the preliminary findings of the PhaseIII clinical trials for CellCept(R), a potential treatment forlupus kidney disease being tested by Aspreva...

Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis

VICTORIA, BC, Canada and BASEL, Switzerland, June 27 /CNW/ -Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) andRoche today released preliminary results for a clinical trialcomparing CellCept (oral mycophenolate mofetil, MMF) to intravenouscyclophosphamide (IVC), which is the current standard of care, forinducing treatment response in the induction phase of patientssuffering fro...

Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine

LIVINGSTON, N.J.--(BUSINESS WIRE)--Jun 27, 2007 - ColumbiaLaboratories, Inc. (NASDAQ: CBRX) today announced positive resultsfrom a recently-completed multi-dose pharmacokinetic study ofvaginally-administered lidocaine, which the Company is developingto prevent and treat dysmenorrhea. This 42-subject study was designed to provide data on bloodlevels associated with the Company's bioadhesiv...

Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announcedpreliminary results from two open-label, multi-center Phase 2clinical trials supporting the potential use of Xcytrin(R)(motexafin gadolinium) Injection, the company's lead productcandidate, in combination with Alimta(R) (pemetrexed) and incombination with Taxotere(R) (docetaxel...

Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839

LOUISVILLE, Colo., June 26, 2007 /PRNewswire-FirstCall/ --Replidyne, Inc. today announced results from three Phase I trialsstudying REP8839, a novel topical antibiotic that has shown potentin vitro activity against major skin pathogens includingmethicillin-resistant S. aureus (MRSA). The results of the Phase Itrials show that topically applied REP8839 appears safe,well-tolerated and asso...

Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis

EVRY, France, June 25, 2007 /PRNewswire/ -- Novagali Pharma, anemerging pharmaceutical company specialized in ophthalmologypresents positive results of its pivotal phase III clinical trialpositive results from the Phase III clinical study of Vekacia(R) inchildren suffering from Vernal Keratoconjunctivitis (VKC) at theXIV Afro-Asian Congress of ophthalmology (AACO) held from June 20to 25...

First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes

-- Additional Findings Reported on Glucose Homeostasis Effects inNormal and Diabetic Rats -- CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- In a 14-day,Phase IIa study of the safety profile of multiple doses of theinvestigational compound dapagliflozin, a selective inhibitor ofthe Sodium-Glucose Transporter 2 (SGLT2) administered alone orconcomitantly with metformin in subjects with Typ...

Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target

New study demonstrates 75% of patients receiving highest doseachieves A1c with no associated hypoglycemia CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- According tofindings presented today at the 67th Scientific Sessions of theAmerican Diabetes Association (ADA) in Chicago, Illinois, theinvestigational treatment liraglutide, a once- daily dose of humanGLP-1 analog under development by...

Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Company's Dermal Drug Delivery Technology

MELBOURNE, Australia, June 25, 2007 /PRNewswire-FirstCall/ --Phosphagenics Limited (AIM: PSG) announced today positive resultsfrom pre-clinical studies of its TPM-02 dermal drug deliverytechnology formulated with retinoic acid, a leading topicaltreatment for severe acne and an active ingredient used inanti-aging cosmetics. The proof of concept studies showed a three-fold increase i...

Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event

Recent clinical studies support the development of DG041 as aneffective anti-platelet that does not increase bleeding risk REYKJAVIK, Iceland, June 25, 2007 /PRNewswire-FirstCall/ --deCODE genetics today announced progress in the development ofDG041, the company's Phase II developmental compound for theprevention of arterial thrombosis. The results of the Phase IIa andclinical pharmacolog...

Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia

PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - Affymax, Inc.(Nasdaq:AFFY) today announced that additional Phase 2 clinicaltrial results for Hematide(TM) were presented at the European RenalAssociation-EDTA Congress being held in Barcelona, Spain by Iain C.Macdougall, M.D., a Hematide investigator from Kings College,London. Dr. Macdougall's poster included data in previously-treateddialy...

Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA

- ARI-2243 is an highly potent DPP-4 inhibitor, possessing Ki of 27pM BOSTON, June 25, 2007 /PRNewswire/ -- Arisaph Pharmaceuticals,Inc., a privately held drug discovery biopharmaceutical company,announced today the results of its potent, smart DPP-4 inhibitor,ARI-2243, presented at the 67th session of the American DiabetesAssociation meeting in Chicago, Illinois. The results showed that...

CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS

LOS ANGELES--(BUSINESS WIRE)--Jun 25, 2007 - CytRx Corporation(NASDAQ:CYTR), a biopharmaceutical company engaged in thedevelopment and commercialization of human therapeutics, todayreported safety and tolerability results from its previouslyannounced double-blind, placebo-controlled, rising multiple doseclinical trial in healthy volunteers with its drug candidatearimoclomol. CytRx believes...

Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials

BRANFORD, Conn.--(BUSINESS WIRE)--Jun 25, 2007 - NeurogenCorporation (Nasdaq: NRGN) today announced positive top-lineresults from two dose-ranging, Phase 2b clinical trials in chronicinsomnia patients with the Company's proprietary insomnia agent,NG2-73, an alpha-3 preferring GABA(A) partial agonist. Multipleformulations were studied in each trial to determine the bestprofile for rapidity o...

Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting

EXETER, N.H.--(BUSINESS WIRE)--Jun 25, 2007 - BentleyPharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceuticalcompany, today announced positive clinical results in threeCompany-sponsored studies of its investigational drug, Nasulin(TM),an intranasal insulin spray. The data were presented this pastweekend at the American Diabetes Association 67th ScientificSessions in Chicago. In a pl...

Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma

CHICAGO and REGENSBURG - June 21, 2007 - “In anaplasticastrocytoma, AP 12009 as a monotherapy is actually clearly superiorto temozolomide,” Prof. Albert Wong, M.D., StanfordUniversity, California, U.S.A. commented on the international PhaseIIb study with the TGF-beta 2-inhibitor AP 12009, under developmentby Antisense Pharma. Prof. Wong discussed the results of the studyin th...